Glucagon and GLP-1 receptor co-agonist
Mazdutide 6 mg subcutaneous once weekly
MAZD_SC_6MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.64 (0.01 to 48.28) | 0.43 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 4.27 (0.17 to 83.25) | 0.27 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.94 (0.10 to 34.29) | 0.35 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.74 (0.16 to 2.65) | 0.59 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.35 (0.00 to 10.56) | 0.75 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.85 (1.30 to 6.10) | 0.47 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.87 (1.02 to 7.92) | 0.47 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.32 (1.56 to 7.22) | 0.21 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.86 (0.05 to 13.27) | 0.47 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.86 (0.05 to 15.11) | 0.48 |
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -9.61 (-18.70 to 0.87) | 0.85 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -11.44 (-18.85 to -2.90) | 0.73 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 37.87 (3.25 to 166) | 0.82 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 34.09 (3.72 to 218) | 0.86 |
| Overweight or obesity without diabetes (adults) | Weight loss of 15 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 17.29 (2.60 to 133) | 0.85 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 5.84 (0.84 to 57.14) | 0.16 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.42 (0.01 to 16.02) | 0.73 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 8.44 (3.20 to 26.85) | 0.17 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 7.33 (2.27 to 29.07) | 0.31 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.28 (0.93 to 5.65) | 0.42 |
Trials
- NCT04965506A Randomized Phase II Study to Evaluate the Efficacy and Safety of IBI362 Versus Placebo and Dulaglutide in Chinese Patients With Type 2 Diabetes2021 · 252 randomized · 20 weeks
- NCT04904913A Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI362 in Chinese Overweight and Obese Subjects2021 · 248 randomized · 24 weeks
- NCT04466904A Multiple Dose Human Tolerability and Pharmacokinetic Study of IBI362 in Chinese Patients With Type 2 Diabetes Mellitus and Poor Glycemic Control2020 · 43 randomized · 12 weeks